Drugmakers normally want to see a positive stock market reaction to the release of their clinical trial data, but such a surge has landed Medivir in trouble with the Swedish stock exchange. The problem? A conference attendee shared the data on Twitter, sparking a rollercoaster day for Medivir's stock.
Last winter, Google Flu Trends was shown to be a work in progress when it wildly overestimated incidence of influenza, but its algorithm-based model has considerable potential.
Biopharma researchers have accrued a huge library of chemical safety data over the past 60 years, but--as is often the case--much of it is tied up in formats that make computational analysis impossible.
The United Kingdom is moving heavily into sequencing through its 100K Genome Project, but the data is of little use without analytical abilities. With this in mind, the U.K. government has coughed up an extra $16 million to find genomics sequence data analysis and interpretation tools.
With the end of 2013 nearing, market analysts are looking back on the year and forecasting what is next for the industry. Shared, familiar themes are emerging: Biopharma is still struggling to make R&D more productive, and observers are still talking up the potential for technology to ease the industry's woes.
Poor returns led drug developers to exit the antibiotics sector years ago, only for hospital-acquired infections to become a big, deadly and potentially lucrative problem. Big Pharma is returning to the sector, but two academics have a different idea: crowdsource discovery.
With pressure mounting on drugmakers to make clinical trial data more transparent, Pfizer has started to take steps to open up its results, unveiling more concrete details and a timeline for adoption this week.
After suffering a string of late-phase failures in recent years, Merck KGaA is in the middle of restructuring its business and rebuilding its pipeline. This week, the company began working with two potential sources of new drugs when computational biology and antibody discovery startups joined its Israeli bio incubator.
Since 1888, the U.S. has published weekly reports on cases of notifiable diseases, building a huge trove of data in the process. The usefulness of this data was limited by its format, which stopped researchers from effectively mining it for insights, but a massive digitization project has now opened up the information.
When Pfizer began its virtual trial in 2011, the technology it used was at the forefront of innovation in clinical research. Yet two years later, some of the ideas are already looking dated, with the rise of smartphones meaning Pfizer now foresees participants using their own devices, instead of dedicated tools.
Sony has filed a patent for a "SmartWig," a replacement head of hair that also tracks the wearer's blood pressure, temperature and other metrics.
In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease. The work has delivered some insights, but also shown the method has limitations. Now, a new approach could avoid these flaws.
The rise of cybersecurity threats gives biopharma and other industries a new and unfamiliar problem that they are ill-equipped to handle alone. In response, an increasing number of biopharma companies are outsourcing cybersecurity activities, a strategy that has been vindicated by a new report.
The creation of the new site follows a surge in visits by people using mobile devices. Almost 1-in-4 visitors to FDA.gov now uses a mobile device.
Speaking at an investor day late last week, Novartis chief financial officer Harry Kirsch outlined how the company plans to generate "substantial savings" by working with external data management vendors.
While the recent hack of FDA databases raised plenty of questions about its cybersecurity policies, the agency offered few answers. If a damning new report into government-wide practices is in any way representative of the FDA though, the agency will need to tighten up.
In the 20 months since the White House unveiled its $200 million Big Data R&D initiative, the field has matured and begun to fulfill its potential. Now the government has inked a batch of data-related projects and signed up Eli Lilly, Novartis and Pfizer as partners.
With payers in key markets pushing for lower drug prices and generics slaying many of Big Pharma's cash cows, one way companies are trying to achieve efficiency goals is through increased spending on business intelligence and analytics tools.
It is now two months since Google sparked speculation by unveiling vague but ambitious plans to enter the biotech sector. Details of what the spinout, called Calico, will do are still limited, but we now know some of the people who will run the show. Unsurprisingly, Google has poached some heavy hitters.
Frost & Sullivan predicts the falling cost of next-generation sequencing will cause the informatics market to triple in value by 2018.